share_log

The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts

Benzinga ·  Apr 22 21:00

Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Intra-Cellular Therapies (NASDAQ:ITCI) in the last three months.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings85100
Last 30D10000
1M Ago42100
2M Ago22000
3M Ago11000

In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average target of $88.86, a high estimate of $103.00, and a low estimate of $77.00. Marking an increase of 10.55%, the current average surpasses the previous average price target of $80.38.

price target chart

Interpreting Analyst Ratings: A Closer Look

The...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment